EXAS Live signals | Maximize Profits with Getagraph.com

SELL 3707 min ago

@ $45.22

Issued: 31 May 2024 @ 13:25

Return: 0.51%

Previous signal: May 31 - 11:04

Previous signal: Buy

Return: 0.59 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	1.97M
Average Volume	2.99M
Market Cap	8.39B
EPS	$0 ( 2024-05-14 )
Next earnings date	( $-0.230 ) 2024-07-30
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-34.69
ATR14	$1.349 (2.97%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-15	Bloomer Aaron	Sell	51 619	Restricted Stock Units
2024-04-30	Coward D Scott	Buy	218	Common Stock
2024-05-01	Coward D Scott	Sell	67	Common Stock
2024-04-30	Cunningham Everett	Buy	708	Common Stock
2024-05-01	Cunningham Everett	Sell	136	Common Stock

INSIDER POWER
30.71
Last 100 transactions
Buy: 527 629 \| Sell: 272 888

Volume Correlation

Long: 0.65 (weak)

Short: -0.52 (weak negative)

Signal:(52) Neutral

Exact Sciences Corp Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Exact Sciences Corp Correlation - Currency/Commodity

0.60
( weak )

0.40
( neutral )

0.00
( neutral )

0.53
( weak )

0.10
( neutral )

Exact Sciences Corp Financials

Annual	2023
Revenue:	$2.50B
Gross Profit:	$1.85B (73.83 %)
EPS:	$-1.130

FY	2023
Revenue:	$2.50B
Gross Profit:	$1.85B (73.83 %)
EPS:	$-1.130

FY	2022
Revenue:	$2.08B
Gross Profit:	$1.51B (72.44 %)
EPS:	$-3.54

FY	2021
Revenue:	$1.77B
Gross Profit:	$1.31B (74.04 %)
EPS:	$-3.48

Financial Reports:

No articles found.

Exact Sciences Corp Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Exact Sciences Corp

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.